NewLink Genetics Corp.
(NASDAQ : NLNK)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. -1.24%63.151.0%$510.50m
AMGNAmgen, Inc. -4.02%225.591.3%$451.51m
BIIBBiogen, Inc. -2.14%278.141.4%$375.15m
ILMNIllumina, Inc. -2.27%319.583.5%$322.74m
VRTXVertex Pharmaceuticals, Inc. -2.07%229.061.9%$273.01m
REGNRegeneron Pharmaceuticals, Inc. -3.17%345.282.6%$238.76m
EXASEXACT Sciences Corp. -2.83%89.5724.0%$223.37m
ALXNAlexion Pharmaceuticals, Inc. -3.02%105.272.0%$170.84m
AAgilent Technologies, Inc. -0.92%88.251.6%$130.79m
INCYIncyte Corp. -1.92%76.742.5%$127.16m
BMRNBioMarin Pharmaceutical, Inc. 0.61%86.154.3%$108.27m
SRPTSarepta Therapeutics, Inc. -1.14%112.3914.6%$108.00m
SGENSeattle Genetics, Inc. -1.54%113.576.1%$103.89m
BLUEbluebird bio, Inc. -2.74%87.2614.2%$86.40m
DERMDermira, Inc. -0.27%18.713.8%$83.32m

Company Profile

NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.